ES2064887T3 - Composiciones quimicas solidas estabilizadas. - Google Patents

Composiciones quimicas solidas estabilizadas.

Info

Publication number
ES2064887T3
ES2064887T3 ES91202070T ES91202070T ES2064887T3 ES 2064887 T3 ES2064887 T3 ES 2064887T3 ES 91202070 T ES91202070 T ES 91202070T ES 91202070 T ES91202070 T ES 91202070T ES 2064887 T3 ES2064887 T3 ES 2064887T3
Authority
ES
Spain
Prior art keywords
water soluble
alkaline stabilizer
chemical compositions
solid chemical
stabilized solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91202070T
Other languages
English (en)
Inventor
Haan Pieter De
Der Ven Cornelus Josephus Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2064887T3 publication Critical patent/ES2064887T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Developing Agents For Electrophotography (AREA)

Abstract

SE PRESENTAN COMPOSICIONES QUIMICAS (EJ. FARMACEUTICAS) DESHIDRATADAS ESTABILIZADAS QUE CONTIENEN UNA SAL DE ADICION ACIDA DISOLUBLE EN AGUA DE UN COMPUESTO BASICO POCO SOLUBLE (EJ. MIANSERINA, APOMORFINA, CLOROPROMAZINA, IMIPRAMINA O PROMETAZINA); UN EXCIPIENTE SELECCIONADO DEL GRUPO QUE CONSISTE EN CELULOSA MICROCRISTALINA, LACTOSA, FOSFATO DE HIDROGENO CALCICO Y MEZCLAS DEL MISMO; Y UN ESTABILIZADOR ALCALINO DISOLUBLE EN AGUA (> 2 MG/ML). LA COMPOSICION DESHIDRATADA ES RELATIVAMENTE MAS ESTABLE QUE UNA QUE NO CONTIENE EL ESTABILIZADOR ALCALINO DISOLUBLE EN AGUA, ESPECIALMENTE DESPUES DE UN PROCESO DE GRANULACION A ALTA TEMPERATURA. EL PROCESO PARA LA PREPARACION DE LA COMPOSICION DESHIDRATADA ES TAMBIEN MAS "VIGOROSO" CON EL ESTABILIZADOR ALCALINO DISOLUBLE EN AGUA AÑADIDO.
ES91202070T 1990-09-13 1991-08-13 Composiciones quimicas solidas estabilizadas. Expired - Lifetime ES2064887T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58185990A 1990-09-13 1990-09-13

Publications (1)

Publication Number Publication Date
ES2064887T3 true ES2064887T3 (es) 1995-02-01

Family

ID=24326864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91202070T Expired - Lifetime ES2064887T3 (es) 1990-09-13 1991-08-13 Composiciones quimicas solidas estabilizadas.

Country Status (14)

Country Link
EP (1) EP0475482B1 (es)
JP (1) JP3153577B2 (es)
KR (1) KR100196209B1 (es)
AT (1) ATE112491T1 (es)
AU (1) AU643920B2 (es)
CA (1) CA2049811C (es)
DE (1) DE69104453T2 (es)
DK (1) DK0475482T3 (es)
ES (1) ES2064887T3 (es)
FI (1) FI104361B (es)
IE (1) IE65274B1 (es)
NZ (1) NZ239753A (es)
PT (1) PT98955B (es)
ZA (1) ZA916661B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
AU750361B2 (en) * 1997-03-26 2002-07-18 Franciscus W.H.M. Merkus Nasal melatonin composition
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6691057B2 (en) 2001-02-26 2004-02-10 L.U.M. Gesellschaft Fur Labor- Umweltdiagnostic & Medizintechnik Mbh Method and device for accelerated stability analysis
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
KR102416406B1 (ko) * 2019-09-24 2022-07-04 주식회사 종근당 티카그렐러의 산 부가염을 포함하는 안정화된 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US2018410A (en) 1933-12-11 1935-10-22 Victor Chemical Works Dentifrice preparation
US2287699A (en) 1940-02-15 1942-06-23 Monsanto Chemicals Stabilized dicalcium phosphate
US3012852A (en) 1956-06-06 1961-12-12 Monsanto Chemicals Stabilized calcium phosphates and process therefor
DE1277222B (de) 1965-12-22 1968-09-12 Knapsack Ag Verfahren zur Stabilisierung von Dicalciumphosphatdihydrat
NL129434C (es) 1966-03-12
US4128641A (en) 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
DE2648061C2 (de) 1976-10-23 1982-11-04 Hoechst Ag, 6000 Frankfurt Verfahren zum Stabilisieren von Di-calciumhydrogenphosphatdihydrat
DE2741513A1 (de) 1977-09-15 1979-03-22 Benckiser Gmbh Joh A Verfahren zum stabilisieren von calciumhydrogenphosphat-dihydrat gegen hydrolyse
IE52274B1 (en) 1980-12-12 1987-09-02 Stauffer Chemical Co A process of compacting fine particles of calcium phosphate and the compacts obtained thereby
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions

Also Published As

Publication number Publication date
FI914147A0 (fi) 1991-09-03
IE913054A1 (en) 1992-02-25
PT98955B (pt) 1999-02-26
AU643920B2 (en) 1993-11-25
KR100196209B1 (ko) 1999-06-15
PT98955A (pt) 1992-08-31
AU8341691A (en) 1992-03-19
EP0475482A1 (en) 1992-03-18
CA2049811A1 (en) 1992-03-14
FI104361B (fi) 2000-01-14
NZ239753A (en) 1992-10-28
DK0475482T3 (da) 1995-04-03
EP0475482B1 (en) 1994-10-05
DE69104453D1 (de) 1994-11-10
KR920005978A (ko) 1992-04-27
IE65274B1 (en) 1995-10-18
ZA916661B (en) 1992-06-24
FI914147A (fi) 1992-03-14
DE69104453T2 (de) 1995-03-16
ATE112491T1 (de) 1994-10-15
CA2049811C (en) 2002-11-05
JPH0578236A (ja) 1993-03-30
JP3153577B2 (ja) 2001-04-09

Similar Documents

Publication Publication Date Title
ES2064887T3 (es) Composiciones quimicas solidas estabilizadas.
KR0136279B1 (ko) 일정수분을 함유하는 서방형 제제
NO176203C (no) Fremgangsmåte for fremstilling av ibuprofentabletter med forsinket frigjöring
US5350582A (en) Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof
IT1216570B (it) Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
EP0264259B1 (en) Stabilized pharmaceutical compositions
AU751575B2 (en) Pharmaceutical levothyroxine preparation
NO973646D0 (no) Orale doseringsformer inneholdende et <beta>-laktam antibiotikum
BR9609964A (pt) Formulação sólida estável de sal de enalaprila e processo para preparação da mesma
JPS5581596A (en) Composition for determining creatine kinase
KR910011241A (ko) 정제로 직접 압착 가능한 약제학적 분말 조성물을 제조하기 위한 분무 건조법
ZA821036B (en) Acesulfam-containing compositions,tablets on the basis thereof and process for the manufacture of these tablets
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
NO931671L (no) Depot-preparat
KR850008280A (ko) 니페디핀 제제물의 제조방법
ES450520A1 (es) Procedimiento para la obtencion de soluciones solubilizablesy estabilizadas de 2-cloro-11-(4-metil-i-piperazinil)-dibenz(b,f) (1,4) oxazepina.
JPS565412A (en) Pharmaceutical composition
ATE26271T1 (de) Benzhydrylpiperazine-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS55122713A (en) Tablet comprising antibacterial substance
DE3262231D1 (en) A novel vasodilator compound, process for the preparation thereof and pharmaceutical compositions thereform
SE8202254L (sv) 2,4-dioxacyklohexanon-derivat
ES8200364A1 (es) Procedimiento para la obtencion de derivados de la fenotia- zina
TH6020B (th) สูตรผสมเมนาไดโอนไบซัลโฟท์ที่ได้ทำให้เสถียร และการเตรียมสูตรผสมเหล่านี้
JPS5547643A (en) Complex of optically active alanine-nucleus-substituted mandelic acid and its preparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475482

Country of ref document: ES